Woodline Partners’s Aligos Therapeutics ALGS Stock Holding History

Woodline Partners’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Sell	177,362 -111,807	-39%	-$848K	0.01%	848
2025 Q4	$2.7M	Sell	289,169 -179,030	-38%	-$1.69M	0.01%	736
2025 Q3	$4.59M	Sell	468,199 -50,101	-10%	-$458K	0.02%	589
2025 Q2	$3.74M	Buy	518,300 +202,917	+64%	+$1.21M	0.02%	613
2025 Q1	$2.6M	Buy	+315,383	New	+$6.91M	0.02%	626
2024 Q4	–	Sell	-91,971	Closed	-$796K	–	921
2024 Q3	$796K	Buy	91,971 +70,723	+333%	+$880K	0.01%	521
2024 Q2	$186K	Buy	+21,248	New	+$374K	﹤0.01%	534

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Woodline Partners's ALGS Position: Q1 2026 in Review

Woodline Partners reduced its Aligos Therapeutics (ALGS) stake by 39% in Q1 2026, selling an estimated $848K and leaving 177,362 shares worth $1.32M. The position accounts for 0.01% of the portfolio, ranked #848.

Woodline Partners first reported a position in ALGS in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.59M in Q3 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Woodline Partners held 177,362 shares of Aligos Therapeutics worth $1.32M as of Q1 2026.
Woodline Partners sold 111,807 Aligos Therapeutics shares in Q1 2026, an estimated $848K.
Aligos Therapeutics made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #848 holding.
Woodline Partners first reported a position in Aligos Therapeutics in Q2 2024 and has held it in 7 quarters since.
Woodline Partners's Aligos Therapeutics position peaked at $4.59M in Q3 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.